Table 1 Imaging and Clinico-Pathological Factors between Patients with and without Residual ALN metastases after Neoadjuvant Chemotherapy.

Age, years*

45.2 ± 8.3

47.8 ± 8.5

0.110

Initial clinical T stages

0.425

  T1

7 (11.9%)

6 (12.2%)

  T2

39 (66.1%)

29 (59.2%)

  T3

11 (18.6%)

10 (20.4%)

  T4

2 (3.4%)

4 (8.2%)

Initial clinical N stages

0.162

  N0

4 (6.8%)

2 (4.1%)

  N1

26 (44.1%)

16 (32.7%)

  N2

22 (37.3%)

23 (46.9%)

  N3

7 (11.9%)

8 (16.3%)

Histologic grade

0.208

  Low to moderate

42 (71.2%)

40 (81.6%)

  High

17 (28.8%)

9 (18.4)

HR status

0.011

  Negative

30 (50.8%)

13 (26.5%)

  Positive

29 (49.2%)

36 (73.5%)

HER2 status

0.046

  Negative

31 (47.0%)

35 (71.4%)

  Positive

28 (66.7%)

14 (28.6%)

Number of positive ALNs on initial staging MR imaging**

0.032

  <7

51 (86.4%)

34 (69.4%)

  ≥7

8 (13.6%)

15 (30.6%)

Number of positive ALNs on restaging MR imaging**

0.001

  0

43 (72.9%)

20 (40.8%)

  ≥1

16 (27.1%)

29 (59.2%)

Short diameter of the largest ALN on initial staging MR imaging

0.015

  ≤18.0 mm

56 (94.9%)

39 (79.6%)

  >18.0 mm

3 (5.1%)

10 (20.4%)

Short diameter of the largest ALN on restaging MR imaging

0.296

  ≤6.8 mm

44 (74.6%)

32 (65.3%)

  >6.8 mm

15 (25.4%)

17 (34.7%)

Nodal SUVmax on initial staging PET/CT

0.053

  ≤6.4

42 (71.2%)

26 (53.1%)

  >6.4

17 (28.8%)

23 (46.9%)

Nodal SUVmax on restaging PET/CT

0.012

  ≤0.9

59 (100%)

44 (89.8%)

  >0.9

0

5 (10.2%)